Mason says the pill–which appears to work by quieting neurotransmitters associated with alcohol dependence without serious side effects–must be used together with behavioral therapy. The FDA is expected to review trial data by the end of the year. “It’s not magic,” says Mason, a research consultant to the drug’s manufacturer, Lipha Pharmaceuticals, but “I think we’re really starting to make some inroads.”
